Диссертация (1174284), страница 20
Текст из файла (страница 20)
Natural history of hepatitis С /S. Lingala, M. G. Ghany // Gastroenterol. Clin. North. Am. – 2015. – N 44 (4). – P. 717–734.98.Lozano, R. Global and regional mortality from 235 causes of death for 20age groups in 1990 and 2010: a systematic analysis for the global burden of disease study/ R.
Lozano, M. Naghavi, K. Foreman [et al.] // Lancet. – 2012 Dec 15. – N 380 (9859).– P. 2095–2128.99.Mack, C. L. NASPGHAN practice guidelines: Diagnosis and managementof hepatitis C infection in infants, children, and adolescents / C. L. Mack, R. P. GonzalezPeralta, N. Gupta [et al.] // J. Pediatr. Gastroenterol. Nutr. – 2012. – N 54. – P. 838–855.100. Mangia A. Individualizing treatment duration in hepatitis C virus genotype2/3-infected patients // Liver International. 2011. V.31, №. 1. P. 36 41.101.
Manos, M. M. Distribution of hepatitis C virus genotypes in a diverse USintegrated health care population / M. M. Manos, V. A. Shvachko, R. C. Murphy [et al.]// J. Med. Virol. – 2012. – N 84 (11). – P. 1744–1750.102. Martell, M. Hepatitis C virus (ХГС ) circulates as a population of differentbut closely related genomes: quasispecies nature of ХГСgenome distribution /M. Martell, J. Esteban, J.
Quer [et al.] // J. Virol. – 1992. – V. 66 (5). – P. 3225–3229.103. Mathurin, P. ХГС burden in Europe and the possible impact of currenttreatment / P. Mathurin // Dig. Liver Dis. – 2013. – N 45 (Suppl. 5). – S. 314–317.135104. Micallef, J. M. Spontaneous viral clearance following acute hepatitis Cinfection: a systematic review of longitudinal studies / J.
M. Micallef, J. M. Kaldor, G. J.Dore // Journal Viral Hepatitis. – 2006. – Vol. 13 (1). – P. 34–41.105. Miller, R. H. Hepatitis C virus shares amino acid sequence similarity withpestivises and Flaviviruses as well as members of two plant virus supergroups / R. H.Miller, R. H. Purcell // Pnas. (USA). – 1990. – V.
87. – P. 2057–2061..106. Moghaddam, A. ... / A. Moghaddam, E. Melum, N. Reinton [et al.] //Hepatology. – 2011. – V. 53. – P. 746–754. Szabo, E. Viral hepatitis: new data onhepatitis C infection / E. Szabo, G. Lotz, C. Paska [et al.] // Pathology oncology research: POR. – 2003.– N 9 (4). – P. 215–221.107.
Mohd, H. K. Global epidemiology of hepatitis C virus infection: newestimates of age-specific antibody to ХГС seroprevalence / H. K. Mohd, J. Groeger,A. D. Flaxman [et al.] // Hepatology. – 2013. – N 57 (4). – P. 1333–1342.108. Mortada, H. El-Sh. Burden of pediatric hepatitis C / H. El-Sh. Mortada,N. M. Kamal // World J. Gastroenterol. – 2013. – N 19 (44). – P. 7880–7888.109. Mukomolov, S. Hepatitis C in the Russian Federation: challenges and futuredirections / S. Mukomolov, G. Trifonova, I.
Levakova [et al.] // Hepat. Med. – 2016. – V.8. – Р. 51–60.110. Murray, K. F. Liver histology and alanine amino transferase levels inchildren and adults with chronic hepatitis C infection / K. F. Murray, L. S. Finn, S. L.Taylor [et al.] // Pediatr. Gastroenterol. Nutr. – 2005. – N 41 (5). – P. 634–638.111. Napoli, N. Predictive value of early virological response to treatment withdifferent interferon-based regimens plus ribavirin in patients with chronic hepatitis C / N.Napoli, G. Giannelli, C.
V. Parisi [et al.] // New Microbiol. – 2005. – N 28 (1). – P. 13–21.112. Pawlotsky, J. M. EASL recommendations on treatment of hepatitis C / J. M.Pawlotsky, A. Aghemo, D. Back [et al.] // J. Hepatol. – 2015. – N 63. – P. 199–236.136113. Pawlowska, M. Virologic response to treatment with pegylated interferonalfa-2b and Ribavirin for chronic hepatitis C in children / M. Pawlowska, M.
PilarczykW. Halota // Med. Sci. Monit. – 2010. – N 16. – P. 616–621.114. Pier-Angelo, T. Vertically acquired hepatitis C virus infection: Correlates oftransmission and disease progression / T. Pier-Angelo, C. Calitri, C. Scolfaro [et al.] //World J. Gastroenterol. – 2016 Jan 28.
– N 22 (4). – P. 1382–1392.115. Polis, C. B. Impact of maternal HIV coinfection on the vertical transmissionof hepatitis C virus: a meta-analysis / C. B. Polis, S. N Shah, K. E. Johnson [et al.] // Clin.Infect. Dis. – 2007. – N 44. – P. 1123–1131.116. Prince, A. M. Visualization of hepatitis C virions and putative defectiveinterfering particles isolated from low-density lipoproteins / A. M. Prince, T.
HuimaByron , T. S. Parker [et al.] // J. Viral. Hepatitis. – 1996. – V. 3. – P. 11–17.117. Resti, M. Maternal drug use is a preeminent risk factor for mother-to-childhepatitis C virus transmission: results from a multicenter study of 1372 mother-infantpairs / M. Resti, C. Azzari, L. Galli L. [et al.] // J. Infect. Dis. – 2002. – N.
185. – P. 567–572.118. Robbins, P. W. Classification, nomenclature, and database development forhepatitis C virus (ХГС ) and related viruses: proposal for standardization. Internationalcommittee on virus taxonomy / P. W. Robbins, G. Myers, C. Howard [et al.] // Arch.Virol. – 1998. – V. 143. – P. 2493–2503.119. Roberts, E. A. Maternal-infant transmission of hepatitis C virus infection /E. A. Roberts, L. Yeung // Hepatology. – 2002. – N 36. – P. 106–113120. Rosen, I Pegylated interferon alfa and ribavirin for children with chronichepatitis C / I.
Rose, M. Kori, O. E. Adiv [et al.] // World J. Gastroenterol. – 2013. – N19 (7). – P. 1098–1103.121. Rumbo, C. Hepatitis C in children: a quaternary referral center perspective /C. Rumbo, R. L. Fawaz, S. H. Emre [et al.] // J. Pediatr. Gastroenterol. Nutr. – 2006. – N43. – P. 209–216.137122. Schwarz, K. B. The combination of ribavirin and peginterferon is superior topeginterferon and placebo for children and adolescents with chronic hepatitis C / K. B.Schwarz, R.
P. Gonzalez-Peralta RP, K. F. Murray [et al.] // Gastroenterology. – 2011. –N 140. – P. 450–458.123. Schwarz, K. Sofosbuvir + Ribavirin for 12 or 24 Weeks is Safe and Effectivein Adolescents with Genotype 2 or Genotype 3 Chronic Hepatitis C Infection (presentedat AASLD, November 11-15, 2016) / K. Schwarz, P. Rosenthal, R.
Gonzalez-Peralta [etal.]. – Boston, MA, 2016.124. Shaker. Single-Nucleotide Polymorphisms of IL-10 and IL-28B asPredictors of the Response of IFN Therapy in ХГС Genotype 4-infected Children /Shaker, G. Olfat, Nassar [et al.] // Journal of Pediatric Gastroenterology and Nutrition. –2013. – N 2 (57). –P. 155–160.125. Sherlock, S. Viralhepatitis C / S.
Sherlock // Current opinion ingastroenterology. – 1993. – N 9. – P. 341–348.126. Shiraki, K. Guidelines for care of pregnant women carrying hepatitis C virusand their infants / K. Shiraki, H. Ohto, N. Inaba [et al.] // Pediatr. Int. – 2008. – N 50.
–P. 138–140.127. Sievert, W. A systematic review of hepatitis C virus epidemiology in Asia,Australia and Egypt / W. Sievert, I. Altraif, H. A. Razavi [et al.] // Liver. Int. – 2011. –N 31 (Suppl. 2). – P. 61–80.128. Simmonds, P. Classification of hepatitis C virus into six major genotypesand series of subtypes by phylogenetic analysis of the NS-5 region / P. Simmonds,E. C. Holmes, S. W. Cha [et al.] // J. Gen. Virol.
– 1993. – V. 74. – P. 2391–2399.129. Simmonds, P. A proposed system for the nomenclature of hepatitis C viralgenotypes / P. Simmonds, A. Alberti, H. J. Alter [et al.] // Hepatology. – 1994. – N 19. –P. 1321–1324.130. Smith, D. B. Expanded classification of hepatitis C virus into 7 genotypesand 67 Subtypes: updated criteria and genotype assignment web resource / D. B. Smith,J.
Bukh, K. Kuiken [et al.] // Hepatology. – 2014. – V. 59. – P. 318–327.138131. Sokal, E. M. Peginterferon alfa-2a plus ribavirin for chronic hepatitis Cvirus infection in childrenand adolescents / E. M. Sokal, A. Bourgois, X. [et al.] //J. Hepatol. – 2010. – N 52. – P. 827–831.132. Stättermayer, A. F. Impact of IL28B genotype on the early and sustainedvirologic response in treatment-naive patients with chronic hepatitis C / A. F.Stättermayer, R.
Stauber, H. Hofer [et al.] // Clin. Gastroenterol. Hepatol. – 2011. – N. 9.– P. 344–350.133. Suzuki, T. Morphogenesis of infectious hepatitis C virus particles / T. Suzuki// Front Microbiol. – 2012. – V. 7 (3). – N 38 – P. 1–11.134. Syriopoulou, V. Mother to child transmission of hepatitis C virus: rate ofinfection and risk factors / V. Syriopoulou, G. Nikolopoulou, G. L. Daikos [et al.] //Scand. J. Infect.
Dis. – 2005. – N 37. – P. 350–353..135. Szabo, E. Viral hepatitis: new data on hepatitis C infection / E. Szabo, G.Lotz, C. Paska [et al.] // Pathology oncology research : POR. – 2003.– N 9 (4). – P. 215–221.136. Tanaka, Y. Genome-wide association of IL28B with response to pegylatedinterferon-alpha and ribavirin therapy for chronic hepatitis C / Y. Tanaka, N. Nishida,M. Sugiyama [et al.] // Nat. Genet.
– 2009. – N 41. – P. 1105–1109.137. Thein HH, Yi Q, Dore GJ, Krahn MD. Estimation of stage-specific fibrosisprogression rates in chronic hepatitis C virus infection: a meta-analysis and metaregression. Hepatology. 2008;48(2):418–31.138. Thomas, D. L. Genetic variation in IL28B and spontaneous clearance ofhepatitis C virus / D. L. Thomas, C. L. Thio, M.
P. Martin [et al.] // Nature. –2009. –N 461. – P. 798–801.139. Thompson, A. J. Genetic factors and hepatitis C virus infection / A. J.Thompson // Gastroenterology. – 2012. – Vol. 142. – P.1335—1339.140. Thursz, M. ХГС transmission in industrialized countries and resourceconstrained areas / M. Thursz, A.
Fontanet // Nat. Rev. Gastroenterol. Hepatol. – 2014. –N 11. – P. 28–35.139141. Uhanova, J. A population-based study of the epidemiology of hepatitis C ina North American population / J. Uhanova, R. B. Tate, D. J. Tataryn [et al.] // J. Hepatol. –2012. – N 57. – P. 736–742.142. WHO. Global Hepatitis Report 2017. – Geneva : World Health Organization,2017. – URL: http://www.who.int/hepatitis/publications/global-hepatitis-report2017/en/(accessed 20.08.2017).143. WHO. Growth reference data for 5–19 years. – URL: http://www.who.int/hepatitis/publications/global-hepatitis-report2017/en/ (accessed 13.09.2016).144.
![](https://s.studizba.com/z.php?f=/templates/si/i/noavatar.png&w=100&h=100&t=1"){kind=avatar}
